Literature DB >> 19148305

Hepatitis C Viral Kinetics in Special Populations.

Harel Dahari1, Jennifer E Layden-Almer, Alan S Perelson, Thomas J Layden.   

Abstract

Mathematical models of hepatitis C viral (HCV) kinetics provide a means of estimating the antiviral effectiveness of therapy, the rate of virion clearance and the rate of loss of HCV-infected cells. They have also proved useful in evaluating the extrahepatic contribution to HCV plasma viremia and they have suggested mechanisms of action for both interferon-α and ribavirin. Viral kinetic models can explain the observed HCV RNA profiles under treatment, e.g., flat partial response, biphasic and triphasic viral decay and viral rebound. Current therapy with (pegylated) interferon-α and ribavirin has a poorer success in patients having insulin resistance, hepatic fibrosis, African American ethnicity, HCV/HIV-coinfection, HCV genotype-1 and high baseline viral load. The use of mathematical modeling and statistical analysis of experimental data have been useful in understanding some of these treatment obstacles.

Entities:  

Year:  2008        PMID: 19148305      PMCID: PMC2626272          DOI: 10.1007/s11901-008-0022-2

Source DB:  PubMed          Journal:  Curr Hepat Rep        ISSN: 1540-3416


  46 in total

1.  Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.

Authors:  Harel Dahari; Alan S Perelson
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

2.  Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.

Authors:  J Westin; M Lagging; A P Dhillon; G Norkrans; A I Romero; J-M Pawlotsky; S Zeuzem; S W Schalm; E Verheij-Hart; F Negro; G Missale; A U Neumann; K Hellstrand
Journal:  J Viral Hepat       Date:  2007-01       Impact factor: 3.728

3.  Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation.

Authors:  Harel Dahari; Anna Feliu; Montserrat Garcia-Retortillo; Xavier Forns; Avidan U Neumann
Journal:  J Hepatol       Date:  2005-01-13       Impact factor: 25.083

4.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

5.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

6.  Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.

Authors:  L M Wein; R M D'Amato; A S Perelson
Journal:  J Theor Biol       Date:  1998-05-07       Impact factor: 2.691

7.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Dynamics of alanine aminotransferase during hepatitis C virus treatment.

Authors:  Ruy M Ribeiro; Jennifer Layden-Almer; Kimberly A Powers; Thomas J Layden; Alan S Perelson
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

9.  First phase hepatitis c viral kinetics in previous nonresponders patients.

Authors:  S J Cotler; J E Layden; A U Neumann; D M Jensen
Journal:  J Viral Hepat       Date:  2003-01       Impact factor: 3.728

10.  Antiviral action of ribavirin in chronic hepatitis C.

Authors:  Jean-Michel Pawlotsky; Harel Dahari; Avidan U Neumann; Christophe Hezode; Georgios Germanidis; Isabelle Lonjon; Laurent Castera; Daniel Dhumeaux
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  8 in total

Review 1.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

2.  Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.

Authors:  M K Baum; S Sales; D T Jayaweera; S Lai; G Bradwin; C Rafie; J B Page; A Campa
Journal:  HIV Med       Date:  2011-02       Impact factor: 3.180

3.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Authors:  Harel Dahari; Jeremie Guedj; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2011-07-02

4.  Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.

Authors:  E S A Araújo; H Dahari; A U Neumann; N de Paula Cavalheiro; C E Melo; E S de Melo; T J Layden; S J Cotler; A A Barone
Journal:  J Viral Hepat       Date:  2011-04       Impact factor: 3.728

5.  Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon.

Authors:  Harel Dahari; Bruno Sainz; Alan S Perelson; Susan L Uprichard
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

6.  HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.

Authors:  N Laufer; F Bolcic; M J Rolón; A Martinez; R Reynoso; H Pérez; H Salomón; P Cahn; J Quarleri
Journal:  Antiviral Res       Date:  2011-03-02       Impact factor: 5.970

Review 7.  Quantification of viral infection dynamics in animal experiments.

Authors:  Shingo Iwami; Yoshiki Koizumi; Hiroki Ikeda; Yusuke Kakizoe
Journal:  Front Microbiol       Date:  2013-09-10       Impact factor: 5.640

8.  Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.

Authors:  Tsunamasa Watanabe; Fuminaka Sugauchi; Yasuhito Tanaka; Kentaro Matsuura; Hiroshi Yatsuhashi; Shuko Murakami; Sayuki Iijima; Etsuko Iio; Masaya Sugiyama; Takashi Shimada; Masakazu Kakuni; Michinori Kohara; Masashi Mizokami
Journal:  Gut       Date:  2012-11-07       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.